Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)

BACKGROUND: Eribulin mesylate, a synthetic analog of halichondrin B, is a novel tubulin-binding agent that inhibits cancer cell proliferation at low-nanomolar levels. METHODS: In a multicenter ECOG trial, patients with progressive metastatic CRPC, ECOG 0-2 were treated with eribulin 1.4 mg/m(2) as a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Am J Clin Oncol
Glavni autori: Stein, Mark N., Chen, Yu-Hui, Carducci, Michael A., Hudes, Gary R., Lerma, Pauline M., Tan, Winston W., Dalune, Robert, Rowland, Kendrith M., Kuzel, Timothy M., DiPaola, Robert S.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2019
Teme:
Original Articles: Genitourinary
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212786/
https://ncbi.nlm.nih.gov/pubmed/30789412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000526
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items